Cerus Shares Rise on Positive Results for Intercept Blood Cells Trial
By Dean Seal
Shares of Cerus gained after positive results were disclosed in a Phase 3 trial of its INTERCEPT Red Blood Cells being transfused to complex cardiac surgery patients.
The stock rose 10% to $2.05 in the first few hours of the trading day. Shares are still 5% lower than where they started the year.
The biotechnology company said Tuesday that the trial met its primary efficacy endpoint and showed non-inferiority for the INTERCEPT blood cells compared with conventional red blood cells as measured by incidence of acute kidney injury.
Cerus anticipated initiating a premarket approval application with the U.S. Food and Drug Administration in the second half of next year.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
March 19, 2024 12:12 ET (16:12 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks